The present invention relates to vanilloid receptor-2, a novel member of the
vanilloid receptor family. The invention provides isolated nucleic acid molecules
encoding human VR2 receptors. VR2 polypeptides are also provided, as are vectors,
host cells and recombinant methods for producing the same. The invention further
relates to screening methods for identifying agonists and antagonists of VR2 receptor
activity. Also provided are diagnostic methods for detecting disease states related
to the aberrant expression of VR2 receptors. Further provided are therapeutic methods
for treating disease states including, but not limited to, chronic pain syndromes,
congenital pain insensitivity, inflammation, ischemia, host defense dysfunction,
immune surveillance dysfunction, arthritis, multiple sclerosis, autoimmunity, immune
dysfunction, and allergy.
